课题基金 / 基金详情

Adeno-Associated Virus Gene Therapy Vectors: Molecular Interactions on Cell Entry

Adeno-Associated Virus Gene Therapy Vectors: Molecular Interactions on Cell Entry
腺相关病毒基因治疗载体:进入细胞时的分子相互作用
批准号:
10552417
负责人:
MICHAEL S. CHAPMAN
金额:
$77.96万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
未结题
起止时间:
2017-08-01 至 2028-07-31

项目摘要

项目成果

MICHAEL S. CHAPMAN的其他基金

相似基金

相关文献

中文摘要
翻译
项目总结/摘要 腺相关病毒(AAV)是一种用于广泛的基因治疗的主要递送载体。 疾病和偏好。FDA最近批准了AAV介导的脊髓肌肉萎缩症治疗。 萎缩(SMA)和RPE相关的视网膜营养不良,而150项临床试验正在进行中。然而,效率低下 转导需要高剂量,具有免疫毒性的风险,这在临床试验中是显而易见的。 AAV细胞转导所需的宿主蛋白质的全基因组筛选改变了人们的理解, 的AAV入口。迄今为止未表征的AAVR被鉴定为关键受体,而AAVR的下游作用被证实是重要的。 GPR 108最有可能参与内体逃逸。AAVR cryo-EM结构将置于生物背景下。 GPR 108的研究将从精确定位AAV和GPR 108结合的进入步骤和细胞位置开始, 以及鉴定与AAV相互作用的结构域。结构办法将是整体性的。整体 该构型将来自与天然样GPR 108复合的AAV的冷冻电子断层扫描(ET 纳米盘这将与AAV的高分辨率冷冻电子显微镜(EM)结合, 表达的GPR 108的胞外结构域。将研究AAV构象转变的触发因素 其释放病毒隔离的磷脂酶A2用于内体逃逸,因为AAV运输到细胞核。 AAV的抗体中和被广泛认为是通过干扰聚糖结合或通过干扰抗体中和而介导的。 进入后的步骤。这将在发现AAVR和几种中和抗体的结合重叠后重新评估。 克隆抗体体内结合的普遍模式将首先通过冷冻EM建立, 来自合并的人血清的多克隆抗体。突变,针对逃跑,将被用来测试 事实上,受体结合和进入是否是中和的主要机制,以及是否逃逸到 可以设计通过预先存在的抗体的快速中和而不损害受体介导的细胞进入。 计算机方法,优化原子结构与冷冻-EM图,在AAV研究期间原型化,将 开发和传播。模块将实现RSRef算法,在匹配地图时是唯一的 值,可细化的实验分辨率的3D原子轮廓的总和。这将与开放的 源力场,打开了一个新兴的应用,原子分辨率低温EM在确定氢 成键网络和质子化状态。对于低于3 μ m的分辨率,限制消除不必要的 将引入自由度以限制过度拟合,过度拟合是EM细化中未被充分认识的问题。 该项目的主要目标是对AAV的宿主相互作用进行分子理解, 和机械基础的工程需要提高载体的效率和特异性, 开发安全的基因疗法。更广泛的附带影响将来自病毒进入的模型系统 这将付诸严格的实际测试,以及提高EM结构精度的计算机方法。
英文摘要
Project Summary / Abstract Adeno-associated virus (AAV) is a leading delivery vector for gene therapies of a wide range of genetic disease and predilections. The FDA has recently approved AAV-mediated treatments for spinal muscular atrophy (SMA) and RPE-associated retinal dystrophy, while 150 clinical trials are ongoing. However, inefficient transduction requires high doses with risk of immunotoxicity that has been evident in clinical trials. A genome-wide screen for host proteins, needed for AAV cell transduction, changed the understanding of AAV entry. Hitherto-uncharacterized AAVR was identified as a key receptor, while the downstream role of GPR108 is most likely in endosomal escape. AAVR cryo-EM structure will be put into biological context. Studies of GPR108 will start by pinpointing the entry step and cell location where AAV and GPR108 associate, and identification of the domains with which AAV interacts. The approach to structure will be holistic. Overall configuration will come from cryo-electron tomography (ET) of AAV complexed with native-like GPR108 nanodiscs. This will be integrated with high resolution cryo-electron microscopy (EM) of AAV complexed with expressed extracellular domains of GPR108. Triggers will be investigated of an AAV conformational transition that releases a virally-sequestered phospholipase A2 for endosomal escape, as AAV traffics to the nucleus. Antibody neutralization of AAV is widely considered mediated by interference with glycan-binding or of a post-entry step. This will be reevaluated after finding overlap in the binding of AAVR and several neutralizing monoclonal antibodies. Prevalent in vivo modes of binding will first be established through cryo-EM using polyclonal antibodies from pooled human serum. Mutations, directed towards escape, will be used to test whether receptor-binding and entry are, in fact, primary mechanisms of neutralization, and whether escape to rapid neutralization by pre-existing antibodies can be designed without harm to receptor-mediated cell entry. Computer methods, optimizing atomic structure vs. cryo-EM maps, prototyped during AAV studies, will be developed and disseminated. Modules will implement the RSRef algorithm, unique in matching to map values, a sum of 3D atomic profiles of refinable experimental resolution. This will be combined with open source force fields, opening an emerging application of atomic resolution cryo-EM in determining hydrogen bonding networks and protonation states. For resolutions below 3 Å, restraints eliminating unnecessary freedom will be introduced to limit the over-fitting that is an under-appreciated problem in EM refinement. The project’s main goal is a molecular understanding of AAV’s host interactions, providing structural and mechanistic foundations for engineering needed improvements in vector efficiency and specificity in development of safe gene therapies. Broader collateral impact will come from a model system for viral entry that will be put to rigorous practical test, and computer methods for improving the precision of EM structures.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1021/acs.chemrev.1c00936
发表时间: 2022-09-14
期刊: CHEMICAL REVIEWS
影响因子: 62.1
作者: [Stagg, Scott M., Yoshioka, Craig, Davulcu, Omar, Chapman, Michael S.]
通讯作者: Chapman, Michael S.
Adeno-Associated Virus Gene Therapy Vectors: Molecular Interactions on Cell Entry
Adeno-Associated Virus Gene Therapy Vectors: Molecular Interactions on Cell Entry
  • 批准号:
    9789047
  • 项目类别:
  • 资助金额:
    $74.1万
  • 财政年份:
    2017
  • 负责人:
    MICHAEL S. CHAPMAN
  • 依托单位:
Adeno-Associated Virus Gene Therapy Vectors: Molecular Interactions on Cell Entry
  • 批准号:
    10224232
  • 项目类别:
  • 资助金额:
    $74.1万
  • 财政年份:
    2017
  • 负责人:
    MICHAEL S. CHAPMAN
  • 依托单位:
Refinement of Macromolecular Assembly Structure using Electron Microscopy
海外基金